| 查看: 124 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Roche provides update on phase III study of Avastin
|
||
|
Roche provides update on phase III study of Avastin in men with late stage prostate cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. Data from the study will be submitted by CALGB for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. “Patients with hormone-refractory prostate cancer are in urgent need of new treatment options. It is unfortunate that the study did not meet its primary objective, however, we look forward to sharing the data with the medical community, including the secondary endpoints,” said Hal Barron, M.D., Head Global Development and Chief Medical Officer at Roche. These findings do not impact Avastin’s approved indications, where Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment. Avastin’s broad development programme in other tumour types will also continue as planned. |
回复此楼» 猜你喜欢
脑梗怎么治疗
已经有3人回复
-
脑梗怎么治疗
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有281人回复
-
如何高效的测量腺病毒的粒径和电位
已经有0人回复
-
生物组织中有目标分析物，专属性怎么做
已经有0人回复
-
26在职申博—生物与医药—抗体/ADC药物方向，江浙沪，有项目，可带资。
已经有1人回复